Abstract: An object of the present invention is to provide a sustained drug release system useful for treating eye diseases. There is provided a device for sustained release of an ophthalmic drug, comprising a drug enclosing part and an intraocular retention gas enclosing part adjacent to the drug enclosing part, the enclosing parts being provided in a hollow container having at least one opening part, wherein the drug enclosing part is isolated from the opening part by the intervention of the intraocular retention gas enclosing part.

Abstract: This invention provides an antitumor drug delivery formulation for treating a subject having a tumor more highly expressing a TUG1 gene than normal tissues or preventing the subject from tumor metastasis, comprising a polymeric micelle comprising a nucleic acid that suppresses high expression of the TUG1 gene as an active ingredient, wherein the polymeric micelle comprises a block copolymer having a cationic poly(amino acid) segment and a hydrophilic polymer chain segment and the nucleic acid, and wherein the nucleic acid is bound to a cationic group of the cationic poly(amino acid) segment to form a complex and/or the nucleic acid is incorporated in the micelle or attached into the micelle; and the polymeric micelle accumulates in the tumor.

Abstract: The present invention addresses the problem of how to provide a predictive marker useful for carcinogenesis surveillance after hepatitis C virus eradication. Provided is a predictive marker composed of a single nucleotide polymorphism specified by rs17047200. In the present invention, the single nucleotide polymorphism is detected in nucleic acid samples collected from subjects, thereby to examine the risk of developing hepatocellular carcinoma after of hepatitis C virus eradication.

Abstract: [Object] To provide a decorative aqueous composition that includes particles formed from opal-type colloidal crystals uniformly and stably dispersed in an aqueous dispersion medium, and exhibits a structural color due to interference of light, and to provide a method for producing the decorative aqueous composition. [Solution] The decorative aqueous composition of the present invention contains particles of opal-type colloidal crystals dispersed in an aqueous dispersion medium in which a polymer is dissolved. The particles of the opal-type colloidal crystals are made from hydrophilic colloidal particles having an average particle diameter ranging from 10 nm to 1000 nm with a variation coefficient of the particle diameter being within 20%. Therefore, the decorative aqueous composition of the present invention contains opal-type colloidal crystals uniformly and stably dispersed in an aqueous dispersion medium, and exhibits a structural color due to interference of light.

Abstract: An object of the present invention is to provide a new means capable of easily and efficiently preparing cells showing a function more similar to the function of intestinal epithelial cells of a living body. According to the present invention, pluripotent stem cells are induced to differentiate into intestinal stem cell-like cells by a method for inducing differentiation of pluripotent stem cells into intestinal epithelial cells, the method including a step (1) of differentiating pluripotent stem, cells into intestinal stem cell-like cells and a step (2) of differentiating the intestinal stem cell-like cells obtained in the step (1) into intestinal epithelial cell-like cells by using an MEK1 inhibitor, a DNA methylation inhibitor, a TGF? receptor inhibitor, EGF, and a cAMP activator in combination.

Abstract: Provided is an ultraviolet irradiation device capable of increasing the irradiance at an affected site (target cells) even when ultraviolet light having the same intensity is emitted. This ultraviolet irradiation device is provided with: a device body configured to be capable of emitting ultraviolet light from a light emission unit; an ultraviolet-transparent substrate disposed on the light emission unit; and an elastic member which is disposed on the surface of the substrate facing away from the device body and made of an ultraviolet-transparent material.

Abstract: An object of the present invention is to provide a photodynamic therapy light irradiation device for irradiating two kinds of light in different wavelength ranges to an irradiated surface, the device being capable of irradiating the light with uniform illuminance to the irradiated surface even having an uneven shape and obtaining a spectral distribution of high uniformity on the entire irradiated surface. A photodynamic therapy light irradiation device of the present invention is characterized by including: a light source unit having one or more LED elements that emit first light having a peak wavelength within a range of wavelengths of not shorter than 400 nm to not longer than 420 nm disposed on a flexible substrate; and a fluorescent plate configured to transmit a part of the first light from the light source unit, and to convert another part thereof into second light having a wavelength of not shorter than 500 nm to not longer than 520 nm and thereby emit the second light.

Abstract: [Object] Provided are a “eutectic colloidal crystal” which is an aggregate of plural kinds of colloidal crystals having different lattice constants, a solidified body of the eutectic colloidal crystal, and methods for producing them. [Resolution means] The eutectic colloidal crystal of the present invention contains two or more kinds of colloidal crystals composed of substantially monodispersed colloidal particles having different particle sizes. This eutectic colloidal crystal is obtained by providing a colloidal dispersion of two or more kinds of colloidal particles having different particle sizes, and a polymer which will not substantially adsorb to the colloidal particles (the coefficient of variation in particle size of these colloidal particles is less than 20%) dissolved in a dispersion medium (dispersion preparation process), and allowing the colloidal dispersion to stand (eutectoid process).

Abstract: A phototherapy device includes a light source module configured to emit therapeutic light to an affected area of a skin. The light source module includes a plurality of LED elements to emit light having a peak wavelength in a range of 365 nm±5 nm, and having a wavelength equal to or shorter than 350 nm. The light source module also includes a light outlet window to which the light emitted from the LED elements is incident and through which the therapeutic light exits. The light source module also includes a filter configured to substantially shield light having a wavelength equal to or shorter than 350 nm when the light emitted from the LED elements passes through the filter.

Abstract: This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a TUG1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression of the TUG1 gene in tumor stem cells.

Abstract: A material for treatment of brain injury, a method for treatment of brain injury, a material for regeneration of brain neurons, and a method for regeneration of brain neurons are provided. The material for treatment of brain injury contains a carrier on which at least one selected from the group consisting of N-cadherin, a fusion protein containing an entire or partial region of N-cadherin, and a fusion protein containing an entire or partial region of a protein having homology to N-cadherin is immobilized or coated.

Abstract: It is an object to provide a culture method which is capable of maintaining and/or culturing iPS cell-derived intestinal stem cells, while maintaining the properties of intestinal stem cells. The induced pluripotent stem cell-derived intestinal stem cell-like cells are cultured in the presence of a GSK-3? inhibitor, a histone deacetylation inhibitor, and a serum replacement, or in the presence of a GSK-3? inhibitor and a serum replacement. Preferably, the culture is carried out under conditions in which one or more compounds selected from the group consisting of an epidermal growth factor, a TGF? receptor inhibitor and a fibroblast growth factor are further present.

Abstract: A screening system provided with a potential-dependent Na ion channel that extends the duration of the action potential associated with depolarization, and a K ion channel that deepens the resting membrane potential in the negative direction, said screening system furthermore including cells provided with ion channels that contribute to deepening the resting membrane potential in the negative direction and/or shortening the duration of the action potential as target ion channels. By such cells, the action of a test compound on the target ion channel can be easily evaluated by providing an inhibitor for the K ion channel to control the probability of cell death.

Abstract: Disclosed herein is a phototherapy device and a phototherapy method that employ an LED as a light source and are capable of achieving an appropriate therapeutic effect while suppressing a healthy portion of a skin from being damaged by light in a short wavelength band. The phototherapy device comprises a light source unit configured to irradiate an affected area with phototherapeutic light in a UV-B region. The light source unit includes an LED element configured to emit light in the UV-B region, and the LED element emits light having a peak wavelength equal to or greater than 312 nm. Also, the LED element preferably emits light having a peak wavelength equal to or less than 315 nm, and the LED element preferably emits light having a light emission spectrum of which full width at half maximum is equal to or less than 20 nm.

Abstract: An anti-hepatitis B virus agent comprising a compound represented by general formula [1], wherein R1 represents an aryl group, which may be substituted, or the like; R2 represents an aryl group, which may be substituted, or the like; and R3 represents a hydrogen atom or the like; or a salt thereof.

Abstract: An alertness device includes: a respiration sensor that obtains respiratory data of a person; a calculation unit; a waveform generation unit that generates a respiratory interval (RI) waveform which is a transition in a predetermined time period of an RI which is an interval for one respiration; and a determination unit. The calculation unit calculates an average value of the RI and RrMSSDn in a predetermined time period. In a case where an average value of the subsequent RI is greater than an average value of the RI directly previous to the subsequent RI and in a case where the RrMSSDn of the subsequent RI is greater than a value which is obtained by multiplying the RrMSSDn of the previous RI by a constant ?, the determination unit determines on the basis of values calculated by the calculation unit that the person is in a state of low alertness.

Abstract: An anti-hepatitis B virus agent comprising a compound represented by general formula [1], wherein R1 represents an aryl group, which may be substituted, or the like; R2 represents an aryl group, which may be substituted, or the like; and R3 represents a hydrogen atom or the like; or a salt thereof.

Abstract: Provided are a photodynamic therapy light irradiating device and a light irradiating method that can achieve an excellent therapeutic effect by short-time light irradiation. The photodynamic therapy light irradiating device of the present invention includes a light source part having a first LED element having a peak wavelength within a wavelength range of 400 to 420 nm and a second LED element having a peak wavelength within a wavelength range of 500 to 520 nm, and a control unit for controlling outputs of the first LED element and the second LED element. When the first LED element and the second LED element that constitute the light source part are turned on, one irradiated site is irradiated with light from the first LED element and light from the second LED element.

Abstract: This invention provides a composition and a method for treating or preventing a subject having a tumor that more highly expresses a TUG1 gene than in normal tissues (e.g., brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, or lymphoma), which composition comprises, as an active ingredient, a nucleic acid that inhibits the high expression of the TUG1 gene in tumor stem cells.

Abstract: The present invention relates to a method for assisting the diagnosis of the condition of myelofibrosis (MF), a method for assisting the prognostic prediction of MF, and a method for monitoring the therapeutic effect on MF. The present invention also relates to an apparatus for executing these methods. Furthermore, the present invention relates to a marker for determining the condition of myelofibrosis.